Next generation prophylactic human papillomavirus vaccines

医学 类病毒颗粒 人乳头瘤病毒疫苗 病毒学 接种疫苗 二价(发动机) 减毒疫苗 免疫学 宫颈癌 生物 HPV感染 癌症 基因 重组DNA 生物化学 化学 有机化学 毒力 内科学 金属
作者
John T. Schiller,Martin Müller
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (5): e217-e225 被引量:125
标识
DOI:10.1016/s1470-2045(14)71179-9
摘要

The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe, effective, and well established prophylactic vaccines. However, they have some inherent limitations, including a fairly high production and delivery cost, virus-type restricted protection, and no reported therapeutic activity, which might be addressed with the development of alternative dosing schedules and vaccine products. A change from a three-dose to a two-dose protocol for the licensed HPV vaccines, especially in younger adolescents (aged 9-13 years), is underway in several countries and is likely to become the future norm. Preliminary evidence suggests that recipients of HPV vaccines might derive prophylactic benefits from one dose of the bivalent vaccine. Substantial interest exists in both the academic and industrial sectors in the development of second-generation L1 VLP vaccines in terms of cost reduction-eg, by production in Escherichia coli or alternative types of yeast. However, Merck's nonavalent vaccine, produced via the Saccharomyces cerevisiae production system that is also used for their quadrivalent vaccine, is the first second-generation HPV VLP vaccine to be available on the market. By contrast, other pharmaceutical companies are developing microbial vectors that deliver L1 genes. These two approaches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever. Prophylactic vaccines that are based on induction of broadly cross-neutralising antibodies to L2, the minor HPV capsid protein, are also being developed both as simple monomeric fusion proteins and as virus-like display vaccines. The strong interest in developing the next generation of vaccines, particularly by manufacturers in middle-to-high income countries, increases the likelihood that vaccine production will become decentralised with the hope that effective HPV vaccines will be made increasingly available in low-resource settings where they are most needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Me发布了新的文献求助10
1秒前
科研小辣鸡完成签到,获得积分10
2秒前
香蕉觅云应助谨慎乞采纳,获得10
2秒前
今后应助博修采纳,获得10
2秒前
feimengxia发布了新的文献求助10
3秒前
舒心以蓝完成签到,获得积分10
4秒前
NexusExplorer应助Nimnse采纳,获得10
5秒前
Nn发布了新的文献求助30
5秒前
红发发布了新的文献求助10
6秒前
英姑应助活泼山雁采纳,获得10
7秒前
小明完成签到,获得积分20
8秒前
9秒前
9秒前
充电宝应助温柔翰采纳,获得10
10秒前
10秒前
11秒前
Zyd完成签到,获得积分10
11秒前
谨慎乞发布了新的文献求助10
14秒前
15秒前
van完成签到,获得积分10
15秒前
宓之云发布了新的文献求助10
15秒前
ggxq发布了新的文献求助10
16秒前
16秒前
17秒前
Nikola完成签到 ,获得积分10
18秒前
小高完成签到,获得积分10
18秒前
小莫发布了新的文献求助10
19秒前
19秒前
19秒前
温柔翰发布了新的文献求助10
20秒前
谨慎乞完成签到,获得积分10
20秒前
24秒前
牛文文发布了新的文献求助10
24秒前
博修发布了新的文献求助10
24秒前
宓之云完成签到,获得积分0
26秒前
活泼山雁发布了新的文献求助10
27秒前
28秒前
红发完成签到,获得积分10
29秒前
大秦完成签到,获得积分10
30秒前
ggxq完成签到,获得积分10
30秒前
高分求助中
【重要!!请各位用户详细阅读此贴】科研通的精品贴汇总(请勿应助) 10000
Plutonium Handbook 1000
Three plays : drama 1000
International Code of Nomenclature for algae, fungi, and plants (Madrid Code) (Regnum Vegetabile) 1000
Semantics for Latin: An Introduction 999
Psychology Applied to Teaching 14th Edition 600
Robot-supported joining of reinforcement textiles with one-sided sewing heads 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4096783
求助须知:如何正确求助?哪些是违规求助? 3634534
关于积分的说明 11521096
捐赠科研通 3345092
什么是DOI,文献DOI怎么找? 1838397
邀请新用户注册赠送积分活动 906026
科研通“疑难数据库(出版商)”最低求助积分说明 823421